MetaCap

Ernexa Therapeutics (ERNA) vs Kairos Pharma (KAPA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ernexa Therapeutics is the larger company by market cap ($2.3 million vs $2.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ERNA-43.10%KAPA-49.90%
+14%-22%-57%
Oct 7, 20261 yearNov 20, 2026
ERNA-43.33%KAPA-46.21%
+2%-23%-49%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ERNA versus KAPA key metrics
MetricERNAKAPA
Share price$1.36$0.4359
Market cap$2.30M$2.04M
1-day change-16.56%-4.62%
EPS (TTM)$-11.22$-2.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-14.08M$-5.45M
52-week high$37.50$7.28
52-week low$1.35$0.381
Distance from 52-week high-96.37%-94.01%
Analyst consensusnonenone
Avg. price target upside+2105.88%+11141.11%
Average volume43.90K364.25K
Shares outstanding1.69M4.69M
Employees51
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Ernexa Therapeutics

ERNA stock →

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Kairos Pharma

KAPA stock →

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

ERNA vs KAPA FAQ

Which is bigger, Ernexa Therapeutics or Kairos Pharma?

Ernexa Therapeutics (ERNA) is larger, with a market capitalization of $2.30M compared with $2.04M for Kairos Pharma (KAPA).

Are Ernexa Therapeutics and Kairos Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons